New Hope Against Breast Cancers That Spread to the Brain
By Dennis Thompson HealthDay Reporter
TUESDAY, Oct. 8, 2024 -- A recently approved targeted chemotherapy drug can significantly extend the lives of advanced breast cancer patients who have developed tumors in their brains, new clinical trial results show.
On average, patients receiving the drug Enhertu (trastuzumab deruxtecan) survived more than 17 months without any progression of their cancer, researchers reported Oct. 4 in the journal Nature Medicine.
More than 60% of patients survived 12 months without further tumor growth, results show.
And in those patients who’d developed brain tumors, more than 70% had their tumors shrink and 90% were alive a year after the start of their treatment, researchers found.
“These findings offer hope to patients with brain metastases in particular,” said co-lead researcher Dr. Nadia Harbeck, director of the breast cancer clinic at Ludwig-Maximilians University of Munich in Germany.
The U.S. Food and Drug Administration approved Enhertu in April for treatment of people with advanced HER2-positive cancers.
HER2 (human epidermal growth factor 2) is a protein that can promote the growth and spread of breast cancer. HER2-positive breast cancers account for up to 20% of all breast cancers, researchers said in background notes.
Enhertu contains trastuzumab and deruxtecan.
Trastuzumab is a monoclonal antibody that targets and attaches to HER2 proteins on a cancer cell. This allows deruxtecan -- a chemo drug -- to enter the cancer cell and kill it off, along with other tumor cells nearby.
“This is why we can use this active ingredient in the first place,” Harbeck said i a university news release. “Otherwise, it would be much too toxic.”
For this new clinical trial, researchers recruited more than 500 HER2-positive breast cancer patients, including 263 whose cancer had spread to their brain. These patients came from 78 cancer centers around the world.
The study was sponsored by the drug companies AstraZeneca and Daiichi Sankyou, which developed and market Enhertu.
Sources
- Ludwig-Maximilians University of Munich, news release, Oct. 4, 2024
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Additional Breast Cancer Scans Can Triple Detection In Women With Dense Breasts
THURSDAY, May 22, 2025 — Louise Duffield, 60, was relieved to receive a normal mammogram result in 2023, but agreed to undergo an additional MRI scan recommended as part of...
Weight Gain, Delayed Motherhood Linked To Breast Cancer Risk
WEDNESDAY, May 14, 2025 — Significant weight gain paired with delayed or foregone motherhood nearly triples a young woman’s risk of later breast cancer, a new study...
AI Can Catch Hard-To-Detect Breast Cancers In Mammograms
WEDNESDAY, May 14, 2025 -- Artificial intelligence (AI) can help prevent breast cancers that develop between routine mammograms, by catching ones that trained radiologists would...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.